Skip Navigation

Publicaciones covid-9

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

LUCIE LOYAL, JULIAN BRAUN, LARISSA HENZE, BEATE KRUSEMANUELA DINGELDEY, ULF REIMER, FLORIAN KERN, TATJANA SCHWARZ, MAIKE MANGOLD, CLARA UNGER, FRIEDERIKE DÖRFLERSHIRIN KADLER, JENNIFER ROSOWSKIKÜBRAH GÜRCANZEHRA UYAR-AYDIN, MARCO FRENTSCHFLORIAN KURTH, KARSTEN SCHNATBAUM, MAREN ECKEY, STEFAN HIPPENSTIEL, ANDREAS HOCKE, MARCEL A. MÜLLER, BIRGIT SAWITZKI, STEFAN MILTENYIFRIEDEMANN PAUL, 0MARCUS A. MALL, HOLGER WENSCHUHSEBASTIAN VOIGT, CHRISTIAN DROSTEN, ROLAND LAUSTERNILS LACHMAN, LEIF-ERIK SANDER, VICTOR M. CORMAN, JOBST RÖHMEL, LIL MEYER-ARNDT, XANDREAS THIEL AND CLAUDIA GIESECKE-THIEL
?  Evaluación: (not yet rated)
Resumen

The functional relevance of pre-existing cross-immunity to SARS-CoV-2 is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)-reactive and SARS-CoV-2-cross-reactive CD4+ T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that pre-existing spike- and S816-830-reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti-SARS-CoV-2-S1-IgG antibodies. Spike-cross-reactive T cells were also activated after primary BNT162b2 COVID-19 mRNA vaccination displaying kinetics similar to secondary immune responses. Our results highlight the functional contribution of pre-existing spike-cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity following primary SARS-CoV-2 immunization and the high rate of asymptomatic/mild COVID-19 disease courses.

Procedencia del autor
Tipo de documento
Observaciones No puedo subir este artículo tiene 7 Mb
Publicado en el sitio 2021-09-13 13:27:19

Comentarios

(aún no hay comentarios disponibles para este recurso)